https://de.marketscreener.com/kurs/aktie/CSTONE-PHARMACEUTICALS-57946082/news/CStone-Pharmaceuticals-gibt-die-NDA-Zulassung-von-GAVRETO-Pralsetinib-zur-Behandlung-von-fortgesch-42757079/?utm_source=telegram&utm_medium=social&utm_campaign=share